Qiao Li
Qiao Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chen Liang
Department of Clinical Medicine, Basic Medical College, Capital Medical University
1 shared publication - Chuanyou Li
Beijing Center for Disease Prevention and Control, China
1 shared publication - Jianzhou Meng
National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China
1 shared publication - Liu Yi
Shanghai Sixth People's Hospital Affiliated to Jiao Tong University School of Medicine
1 shared publication Ruifang Yang
Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
1 shared publication- Shengsheng Liu
Department of Tuberculosis, Anhui Chest Hospital, Hefei 230022, Anhui, China
1 shared publication
Latest Publications
- 5 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 3364-3368
Investigation of short-circuit fault control for aerospace dual three-phase motor drive
This paper will focus on the research of short-circuit faults in dual three-phase electric drive bridge for aviation applications. First, the dynamic process of system under the condition of a single power device short circuit is analyzed. Then, the circuit fault detection and fault -tolerance method is proposed to reduce the braking torque generated from the fault side. The effectiveness of proposed method has been verified by the simulations and experiments. The research will provide theoretical and technical support for the functional safety of aviation electric drive systems.
- 5 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 3364-3368
Investigation of short-circuit fault control for aerospace dual three-phase motor drive
This paper will focus on the research of short-circuit faults in dual three-phase electric drive bridge for aviation applications. First, the dynamic process of system under the condition of a single power device short circuit is analyzed. Then, the circuit fault detection and fault -tolerance method is proposed to reduce the braking torque generated from the fault side. The effectiveness of proposed method has been verified by the simulations and experiments. The research will provide theoretical and technical support for the functional safety of aviation electric drive systems.
- 14 April 2022
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 75 (6) , 333-340
Evaluation of a novel inhibitor of aspartate semialdehyde dehydrogenase as a potent antitubercular agent against Mycobacterium tuberculosis
The in vitro activity of IMB-XMA0038, a novel inhibitor targeting Mycobacterial tuberculosis (Mtb) aspartate semialdehyde dehydrogenase, was evaluated. Minimum inhibitory concentrations (MICs) of IMB-XMA0038 were against 20 Mtb isolates, including H37Rv (ATCC 27294), ten clinical pan-sensitive isolates, and nine clinical multidrug-resistant (MDR) isolates. In addition, minimum bactericidal concentrations (MBCs) were also determined against the H37Rv and 6 MDR isolates (the background information is same as above in order). A model was generated to evaluate IMB-XMA0038 activity against dormant Mtb. The post-antibiotic effect (PAE), an important indicator of antimicrobial drug dosing schedules to obtain efficacy, was determined based on time required for regrowth of Mtb to 50% of the OD600max value after treatment with various concentrations of IMB-XMA0038 and INH. In addition, interactions between IMB-XMA0038 and other anti-tuberculosis drugs, measured using a checkerboard assay, revealed that IMB-XMA0038 MICs of 0.5–1 μg/mL could be achieved in combinations. Synergistic effects were observed for IMB-XMA0038 when used together with almost all other anti-tuberculosis drugs against most Mtb isolates. IMB-XMA0038 exhibited greater activity than rifampin against Mtb under hypoxic conditions, as reflected by CFU decreases of 1.1-log-unit versus 0.8-log-unit, respectively, for IMB-XMA0038 and rifampin concentrations of 4 × MIC. IMB-XMA0038-induced PAEs (9, 10, 11 days) were comparable to INH PAEs (10, 11, 12 days). These findings suggest that addition of IMB-XMA0038 to current therapeutic regimens could be useful to improve the efficacy of treatments for drug-resistant and drug-susceptible TB.
- 14 April 2022
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 75 (6) , 333-340
Evaluation of a novel inhibitor of aspartate semialdehyde dehydrogenase as a potent antitubercular agent against Mycobacterium tuberculosis
The in vitro activity of IMB-XMA0038, a novel inhibitor targeting Mycobacterial tuberculosis (Mtb) aspartate semialdehyde dehydrogenase, was evaluated. Minimum inhibitory concentrations (MICs) of IMB-XMA0038 were against 20 Mtb isolates, including H37Rv (ATCC 27294), ten clinical pan-sensitive isolates, and nine clinical multidrug-resistant (MDR) isolates. In addition, minimum bactericidal concentrations (MBCs) were also determined against the H37Rv and 6 MDR isolates (the background information is same as above in order). A model was generated to evaluate IMB-XMA0038 activity against dormant Mtb. The post-antibiotic effect (PAE), an important indicator of antimicrobial drug dosing schedules to obtain efficacy, was determined based on time required for regrowth of Mtb to 50% of the OD600max value after treatment with various concentrations of IMB-XMA0038 and INH. In addition, interactions between IMB-XMA0038 and other anti-tuberculosis drugs, measured using a checkerboard assay, revealed that IMB-XMA0038 MICs of 0.5–1 μg/mL could be achieved in combinations. Synergistic effects were observed for IMB-XMA0038 when used together with almost all other anti-tuberculosis drugs against most Mtb isolates. IMB-XMA0038 exhibited greater activity than rifampin against Mtb under hypoxic conditions, as reflected by CFU decreases of 1.1-log-unit versus 0.8-log-unit, respectively, for IMB-XMA0038 and rifampin concentrations of 4 × MIC. IMB-XMA0038-induced PAEs (9, 10, 11 days) were comparable to INH PAEs (10, 11, 12 days). These findings suggest that addition of IMB-XMA0038 to current therapeutic regimens could be useful to improve the efficacy of treatments for drug-resistant and drug-susceptible TB.